Table E1.

Propensity score–matched subgroup analyses for association of risk for positive severe acute respiratory syndrome coronavirus 2 test results with chronic rhinosinusitis by COVID-19 outcome among all patients who underwent severe acute respiratory syndrome coronavirus 2 test (propensity score–matched n = 24,434)

Event	Variable	None	CRS
COVID-19	Event n/total n (%)	310/12,217 (2.5)	380/12,217 (3.1)
	Fully adjusted OR‡ (95% CI)	1.0 (reference)	1.22 (1.04-1.42)
Severe outcomes of COVID-19∗	Event n/total n (%)	50/12,217 (0.4)	82/12,217 (0.7)
	Fully adjusted OR‡ (95% CI)	1.0 (reference)	1.61 (1.12-2.29)
Nonsevere outcomes of COVID-19†	Event n/total n (%)	260/12,217 (2.1)	298/12,217 (2.4)
	Fully adjusted OR‡ (95% CI)	1.0 (reference)	1.13 (0.95-1.32)

CI, confidence interval; COVID-19, coronavirus disease 2019; OR, odds ratio.

Bolded data indicate significant differences in the regression model (P < .05).

^∗Severe outcomes of COVID-19 were the need for oxygen therapy, admission to the intensive care unit, invasive ventilation, or death.

^†Nonsevere outcomes of COVID-19 included COVID-19 patients, excluding severe COVID-19 patients.

^‡Fully adjusted for age; sex; region of residence; history of diabetes mellitus, cardiovascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, hypertension, chronic kidney disease, or nasal polyp; Charlson comorbidity index; and previous use of medication (aspirin, metformin, or statin, systemic corticosteroids, or intranasal corticosteroids).